pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 4·1 min read
save

Dimension Capital targets up to $750M for third life-sciences fund after strong portfolio performance

Jun 4, 2026·read at Endpoints ↗DealPositive

Dimension Capital, a New York and San Francisco-based investment firm that blends machine learning with life-science ventures, announced it is launching its third fund.

The firm is seeking up to $750 million in commitments for the new vehicle, which will continue to back companies at the intersection of AI and biotech.

The fundraising effort comes after a recent hot streak in the firm’s portfolio, where several backed companies have reported strong progress, boosting investor confidence.

If successful, the capital will expand Dimension’s ability to support emerging technologies that aim to accelerate drug discovery and development.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Dimension seeks up to $750M for third life sciences fund after string of success”

read at Endpoints ↗
99 words · retrieved Jun 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sionna Therapeutics, Inc.2

related stories

  • Jun 3Mineralys makes money moves before looming hypertension approvalEndpoints
  • Jun 2#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutEndpoints
  • Jun 2Praxis sinks on late-stage study fail for seizure pill, halts second trialEndpoints
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints
  • May 16Makary resigns; Biogen reports Alzheimer’s data; and moreEndpoints